Protagonist Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel peptide-based medicines to address significant unmet medical needs. Their proprietary peptide technology platform enables them to discover and engineer peptides with desired characteristics, leading to multiple peptide-based drug candidates currently in advanced clinical development. Their pipeline includes rusfertide, a hepcidin mimetic being investigated for the treatment of polycythemia vera, and JNJ-2113 (formerly PN-235), an oral peptide IL-23 receptor antagonist partnered with Janssen Pharmaceutical Companies of Johnson & Johnson for the treatment of psoriasis and ulcerative colitis.

Protagonist is committed to a sustainable future, emphasizing environmental responsibility through initiatives like employee support for electric vehicles and flexible work arrangements to reduce carbon footprints. The company prioritizes patient access to their investigational therapies through clinical trials, striving for responsible pricing to ensure affordability. Additionally, they are dedicated to fostering a diverse and inclusive work environment, promoting employee development and offering a comprehensive benefits package. Protagonist's commitment to ethical business practices, research integrity, and community engagement is evident in their comprehensive compliance program and support for educational initiatives.

Protagonist Therapeutics offers flexible work arrangements to reduce Bay Area traffic congestion and minimize the company's carbon footprint. While details on specific flexible work options are not explicitly mentioned, the company encourages its employees to work remotely at least part-time, particularly non-laboratory staff.

Protagonist Therapeutics offers a competitive benefits package for employees, including 100% coverage of monthly healthcare premiums, 401(k) matching contributions, an employee stock purchase plan, and access to Employee Assistance Programs to address personal and professional challenges. The company is committed to attracting and retaining talented individuals by providing a comprehensive benefits package that supports employee well-being and professional development.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on developing groundbreaking new medicines to treat both rare and prevalent diseases. Their peptide technology platform uses multiple tools and methods to create peptide-based treatments for blood disorders and inflammatory and immunomodulatory diseases, with a specific focus on polycythemia vera, ulcerative colitis, and psoriasis. Protagonist is committed to improving patients' lives by providing access to their innovative therapies and advancing clinical discovery in their areas of focus.

Protagonist Therapeutics promotes a culture that values its employees and patients. They strive to create a supportive and collaborative work environment where every voice is heard and diverse perspectives are encouraged. They are committed to innovation and are undaunted by failure, always seeking to improve upon their successes. They believe in treating patients with respect and are committed to providing them with access to their medicines.

Protagonist Therapeutics is committed to fostering a diverse and inclusive workplace. They track diversity within their workforce and actively seek to interview diverse candidates for open positions. They recognize the importance of a welcoming corporate culture and the value of diverse perspectives in decision-making. The company's board of directors prioritizes diversity in its composition, ensuring representation of different talents, skills, backgrounds, and expertise. Protagonist's commitment to diversity and inclusion is seen as integral to their long-term success.